Healthcare provider profile · identity verified

Stephen Brett Flack, M. D.

Family Practice · CHAMBERSBURG, PA · NPI 1396742631

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Lisinopril	Lisinopril	342	91
Atorvastatin Calcium	Atorvastatin Calcium	334	95
Levothyroxine Sodium	Levothyroxine Sodium	265	62
Amlodipine Besylate	Amlodipine Besylate	254	64
Omeprazole	Omeprazole	231	60
Gabapentin	Gabapentin	228	54
Metformin Hcl	Metformin Hcl	204	58
Duloxetine Hcl	Duloxetine Hcl	188	38
Montelukast Sodium	Montelukast Sodium	170	45
Metoprolol Succinate	Metoprolol Succinate	168	44
Simvastatin	Simvastatin	166	37
Rosuvastatin Calcium	Rosuvastatin Calcium	157	36
Losartan Potassium	Losartan Potassium	151	39
Hydrochlorothiazide	Hydrochlorothiazide	147	40
Pantoprazole Sodium	Pantoprazole Sodium	132	41
Fluticasone Propionate	Fluticasone Propionate	124	47
Famotidine	Famotidine	111	31
Eliquis	Apixaban	102	20
Buspirone Hcl	Buspirone Hcl	97	24
Metoprolol Tartrate	Metoprolol Tartrate	96	17
Pravastatin Sodium	Pravastatin Sodium	89	21
Meloxicam	Meloxicam	85	28
Potassium Chloride	Potassium Chloride	85	28
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	82	18
Tamsulosin Hcl	Tamsulosin Hcl	81	28
Tramadol Hcl	Tramadol Hcl	79	29
Jardiance	Empagliflozin	78	19
Furosemide	Furosemide	75	34
Escitalopram Oxalate	Escitalopram Oxalate	71	19
Allopurinol	Allopurinol	61	18
Carvedilol	Carvedilol	57	15
Xarelto	Rivaroxaban	56	suppressed
Lovastatin	Lovastatin	54	15
Citalopram Hbr	Citalopram Hydrobromide	53	15
Baclofen	Baclofen	51	17
Prednisone	Prednisone	49	38
Clopidogrel	Clopidogrel Bisulfate	48	15
Spironolactone	Spironolactone	45	11
Alprazolam	Alprazolam	43	13
Albuterol Sulfate Hfa	Albuterol Sulfate	39	24
Metformin Hcl Er	Metformin Hcl	38	14
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	37	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	36	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	35	suppressed
Sertraline Hcl	Sertraline Hcl	34	suppressed
Topiramate	Topiramate	33	suppressed
Trazodone Hcl	Trazodone Hcl	32	12
Valsartan	Valsartan	27	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	26	suppressed
Hydrocortisone	Hydrocortisone	26	16
Trulicity	Dulaglutide	26	suppressed
Levetiracetam	Levetiracetam	25	suppressed
Ozempic	Semaglutide	25	suppressed
Bupropion Hcl Sr	Bupropion Hcl	24	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	24	suppressed
Risperidone	Risperidone	24	suppressed
Synthroid	Levothyroxine Sodium	24	11
Arnuity Ellipta	Fluticasone Furoate	23	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	23	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	23	suppressed
Ropinirole Hcl	Ropinirole Hcl	23	suppressed
Glipizide Er	Glipizide	22	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	22	suppressed
Pregabalin	Pregabalin	22	suppressed
Propranolol Hcl	Propranolol Hcl	22	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	21	suppressed
Lansoprazole	Lansoprazole	20	suppressed
Nystatin	Nystatin	20	suppressed
Oxycodone Hcl	Oxycodone Hcl	20	suppressed
Mirtazapine	Mirtazapine	19	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	18	suppressed
Ibandronate Sodium	Ibandronate Sodium	18	suppressed
Ipratropium Bromide	Ipratropium Bromide	18	suppressed
Lorazepam	Lorazepam	18	11
Triamcinolone Acetonide	Triamcinolone Acetonide	18	11
Warfarin Sodium	Warfarin Sodium	18	suppressed
Cephalexin	Cephalexin	17	17
Clonidine Hcl	Clonidine Hcl	17	suppressed
Finasteride	Finasteride	17	suppressed
Glipizide	Glipizide	17	suppressed
Benazepril Hcl	Benazepril Hcl	16	suppressed
Diclofenac Sodium	Diclofenac Sodium	16	suppressed
Bisoprolol-Hydrochlorothiazide	Bisoprolol/Hydrochlorothiazide	15	suppressed
Celecoxib	Celecoxib	15	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	15	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	15	suppressed
Invokana	Canagliflozin	15	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	15	suppressed
Azithromycin	Azithromycin	14	13
Gemfibrozil	Gemfibrozil	14	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	14	suppressed
Primidone	Primidone	14	suppressed
Verapamil Er	Verapamil Hcl	14	suppressed
Atenolol	Atenolol	13	suppressed
Dexlansoprazole Dr	Dexlansoprazole	13	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	13	suppressed
Divalproex Sodium	Divalproex Sodium	13	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	13	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	13	suppressed
Ondansetron Hcl	Ondansetron Hcl	13	suppressed
Ramipril	Ramipril	13	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	13	suppressed
Combivent Respimat	Ipratropium/Albuterol Sulfate	12	suppressed
Fenofibrate	Fenofibrate	12	suppressed
Fluvoxamine Maleate	Fluvoxamine Maleate	12	suppressed
Ketoconazole	Ketoconazole	12	suppressed
Meclizine Hcl	Meclizine Hcl	12	suppressed
Naproxen	Naproxen	12	suppressed
Alendronate Sodium	Alendronate Sodium	11	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	11	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	11	suppressed
Efavirenz-Emtric-Tenofov Disop	Efavirenz/Emtricit/Tenofovr Df	11	suppressed
Ibuprofen	Ibuprofen	11	suppressed
Januvia	Sitagliptin Phosphate	11	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	11	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error